In 2022, the highest cancer rate for men and women among European countries was in Denmark with 728.5 cancer cases per 100,000 population. Ireland and the Netherlands followed, with 641.6 and 641.4 people diagnosed with cancer per 100,000 population, respectively.
Lung cancer Lung cancer is the deadliest type of cancer worldwide, and in Europe, Germany was the country with the highest number of lung cancer deaths in 2022, with 47.7 thousand deaths. However, when looking at the incidence rate of lung cancer, Hungary had the highest for both males and females, with 138.4 and 72.3 cases per 100,000 population, respectively.
Breast cancer Breast cancer is the most common type of cancer among women with an incidence rate of 83.3 cases per 100,000 population in Europe in 2022. Cyprus was the country with the highest incidence of breast cancer, followed by Belgium and France. The mortality rate due to breast cancer was 34.8 deaths per 100,000 population across Europe, and Cyprus was again the country with the highest figure.

In 2022, the incidence of lung cancer among men in Europe was highest in Hungary at 138.4 per 100,000, while Sweden had the lowest incidence. The incidence of lung cancer recorded among women in Denmark was over 79 per 100,000 population. Across the European Union overall, the rate of lung cancer diagnoses was 94.5 per 100,000 among men and 44.1 per 100,000 among women. Smoking and lung cancer risk The connection between smoking and the increased risk of health problems is well established. As of 2021, Hungary had one of the highest daily smoking rates in Europe, with over a quarter of adults smoking daily in the Central European country. The only other countries with a higher share of smoking adults were Bulgaria and Turkey. A positive development though, is the share of adults smoking every day has decreased in almost every European country since 2011. The rise of vaping Originally marketed as a device to help smokers quit, e-cigarettes or vapes have seen increased popularity among people who never smoked cigarettes, especially young people. The use of vapes among young people was reported to be highest in Estonia, Czechia, and Ireland. The dangers of vaping have not been examined over the long term. In the EU there have been attempts to make ‘vapes’ less accessible and appealing for young people, which would include such things as banning flavors and stopping the sale of disposable e-cigarettes.

In 2022, the mortality rate of prostate cancer in Europe was 38.6 per 100,000. Estonia had the highest mortality rate at 80.4 per 100,000, followed by Latvia with 76.1 per 100,000 men. Conversely, Italy had the lowest mortality rate at 25.7 per 100,000. This statistic depicts the mortality rate of prostate cancer Europe in 2022, by country.

In 2022, the mortality rate of breast cancer in women in Europe was **** per 100,000 women. Cyprus had the highest mortality rate at **** per 100,000, followed by Slovakia with **** per 100,000 women. Conversely, Spain had the lowest mortality rate at **** per 100,000. This statistic depicts the mortality rate of breast cancer in Europe in 2022 in women population, by country.

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

Users can access data about cancer statistics, specifically incidence and mortality worldwide for the 27 major types of cancer. Background Cancer Mondial is maintained by the Section of Cancer Information (CIN) of International Agency for Research on Cancer by the World Health Organization. Users can access CIN databases including GLOBOCAN, CI5(Cancer Incidence in Five Continents), WHO, ACCIS(Automated Childhood Cancer Information System), ECO (European Cancer Observatory), NORDCAN and Survcan. User functionality Users can access a variety of databases. CIN Databases: GLOBOCAN provides acces s to the most recent estimates (for 2008) of the incidence of 27 major cancers and mortality from 27 major cancers worldwide. CI5 (Cancer Incidence in Five Continents) provides access to detailed information on the incidence of cancer recorded by cancer registries (regional or national) worldwide. WHO presents long time series of selected cancer mortality recorded in selected countries of the world. Collaborative projects: ACCIS (Automated Childhood Cancer Information System) provides access to data on cancer incidence and survival of children collected by European cancer registries. ECO (European Cancer Observatory) provides access to the estimates (for 2008) of the incidence of, and mortality f rom 25 major cancers in the countries of the European Union (EU-27). NORDCAN presents up-to-date long time series of cancer incidence, mortality, prevalence and survival from 40 cancers recorded by the Nordic countries. SurvCan presents cancer survival data from cancer registries in low and middle income regions of the world. Data Notes Data is available in different formats depending on which type of data is accessed. Some data is available in table, PDF, and html formats. Detailed information about the data is available.

ObjectiveWe investigated whether there are differences in cancer incidence by geographical area of origin in North-eastern Italy.MethodsWe selected all incident cases recorded in the Veneto Tumour Registry in the period 2015-2019. Subjects were classified, based on the country of birth, in six geographical areas of origin (Italy, Highly Developed Countries-HDC, Eastern Europe, Asia, Africa, South-central America). Age-standardized incidence rates and incidence rate ratio (IRR) were calculated, for all cancer sites and for colorectal, liver, breast and cervical cancer separately.ResultsWe recorded 159,486 all-site cancer cases; 5.2% cases occurred in subjects born outside Italy, the majority from High Migratory Pressure Countries (HMPC) (74.3%). Incidence rates were significantly lower in subjects born in HMPC in both sexes. Immigrants, in particular born in Asia and Africa, showed lower rates of all site cancer incidence. The lowest IRR for colorectal cancer was observed in males from South-Central America (IRR 0.19, 95%CI 0.09-0.44) and in females from Asia (IRR 0.32, 95%CI 0.18-0.70). The IRR of breast cancer appeared significantly lower than Italian natives in all female populations, except for those coming from HDC. Females from Eastern Europe showed a higher IRR for cervical cancer (IRR 2.02, 95%CI 1.57-2.61).ConclusionCancer incidence was found lower in subjects born outside Italy, with differences in incidence patterns depending on geographical area of origin and the cancer type in question. Further studies, focused on the country of birth of the immigrant population, would help to identify specific risk factors influencing cancer incidence.

In 2022, Turkey reported a rate of 48 cancer incidents per 100,000 persons per year in the Middle East and North Africa. Morocco, Lebanon, and Tunisia followed with rates between 23 and 26 per 100,000 persons during the same year. Yemen and the United Arab Emirates (UAE) had the lowest crude rate of cancer incidents in the region with 2.5 incidents per 100,000 people.

Nearly 3,900 cancer patients per 100,000 population were recorded in the Mordovia Republic of Russia in 2023, which was the highest prevalence of cases of that disease across the country. The lowest figure was observed in the Tyva Republic almost 1,000 cases per 100,000 inhabitants.

This dataset contains real-world information about colorectal cancer cases from different countries. It includes patient demographics, lifestyle risks, medical history, cancer stage, treatment types, survival chances, and healthcare costs. The dataset follows global trends in colorectal cancer incidence, mortality, and prevention.

Use this dataset to build models for cancer prediction, survival analysis, healthcare cost estimation, and disease risk factors.

Dataset Structure Each row represents an individual case, and the columns include:

Patient_ID (Unique identifier) Country (Based on incidence distribution) Age (Following colorectal cancer age trends) Gender (M/F, considering men have 30-40% higher risk) Cancer_Stage (Localized, Regional, Metastatic) Tumor_Size_mm (Randomized within medical limits) Family_History (Yes/No) Smoking_History (Yes/No) Alcohol_Consumption (Yes/No) Obesity_BMI (Normal/Overweight/Obese) Diet_Risk (Low/Moderate/High) Physical_Activity (Low/Moderate/High) Diabetes (Yes/No) Inflammatory_Bowel_Disease (Yes/No) Genetic_Mutation (Yes/No) Screening_History (Regular/Irregular/Never) Early_Detection (Yes/No) Treatment_Type (Surgery/Chemotherapy/Radiotherapy/Combination) Survival_5_years (Yes/No) Mortality (Yes/No) Healthcare_Costs (Country-dependent, $25K-$100K+) Incidence_Rate_per_100K (Country-level prevalence) Mortality_Rate_per_100K (Country-level mortality) Urban_or_Rural (Urban/Rural) Economic_Classification (Developed/Developing) Healthcare_Access (Low/Moderate/High) Insurance_Status (Insured/Uninsured) Survival_Prediction (Yes/No, based on factors)

In 2022, the mortality rate of lung cancer in the European was **** per 100,000 men and **** per 100,000 women. Among men the mortality rate was highest in Hungary and lowest in Sweden being *** and **** per 100,000 respectively. Hungary was also the country with the highest lung cancer mortality rate in women with **** per 100,000 women. The lowest was in Lithuania with **** per 100,000 women. In most EU countries, there was a marked difference between the mortality of lung cancer in men and women.

The incidence of non-melanoma skin cancer is 17-fold lower in Singapore compared to the UK1, despite Singapore receiving 2-3 times more year-round ultraviolet radiation (UV)2,3. The ageing epidermis of the skin comprises competing somatic mutant clones4,5, from which such cancers develop. We question if differences in keratinocyte skin cancer incidence are reflected in the mutational landscape by comparing ageing facial epidermis from donors of Singapore and the UK. We find UK skin to be a highly competitive, densely mutated landscape with 4-fold greater mutation burden compared to Singaporean skin and differences in clonal selection by country. We disproportionately observe multiple features common to keratinocyte skin cancers6,7,8 in UK skin, such as UV mutagenesis, copy number aberration and hotspot mutations (in particular TP53 R248W). We conclude that keratinocyte skin cancer incidence is reflected in the somatic clones of non-cancerous epidermis. Finally, we re-analyse squamous cell carcinoma exomes from Korea9 to show, even in low incidence populations, carcinogenesis is driven by UV damage.

BackgroundThe nationwide HUN-CANCER EPI study examined cancer incidence and mortality rates in Hungary from 2011 to 2019.MethodsUsing data from the National Health Insurance Fund (NHIF) and Hungarian Central Statistical Office (HCSO), our retrospective study analyzed newly diagnosed malignancies between Jan 1, 2011, and Dec 31, 2019. Age-standardized incidence and mortality rates were calculated for all and for different tumor types using both the 1976 and 2013 European Standard Populations (ESP).FindingsThe number of newly diagnosed cancer cases decreased from 60,554 to 56,675 between 2011–2019. Age-standardized incidence rates were much lower in 2018, than previously estimated (475.5 vs. 580.5/100,000 person-years [PYs] in males and 383.6 vs. 438.5/100,000 PYs in females; ESP 1976). All-site cancer incidence showed a mean annual decrease of 1.9% (95% CI: 2.4%-1.4%) in men and 1.0% (95% CI:1.42%-0.66%) in women, parallel to mortality trends (-1.6% in males and -0.6% in females; ESP 2013). In 2018, the highest age-standardized incidence rates were found for lung (88.3), colorectal (82.2), and prostate cancer (62.3) in men, and breast (104.6), lung (47.7), and colorectal cancer (45.8) in women. The most significant decreases in incidence rates were observed for stomach (4.7%), laryngeal (4.4%), and gallbladder cancers (3.5%), with parallel decreases in mortality rates (3.9%, 2.7% and 3.2%, respectively).InterpretationWe found a lower incidence of newly diagnosed cancer cases for Hungary compared to previous estimates, and decreasing trends in cancer incidence and mortality, in line with global findings and the declining prevalence of smoking.

In 2022, the incidence rate of colorectal cancer in the EU was, among men, 92.7 per 100,000, while among women it stood at 58.2 per 100,000. For men, Hungary had the highest incidence rate at 138.3 per 100,000, while Austria had the lowest at 62.5 per 100,000. For women, Denmark had the highest incidence rate at 95.7 per 100,000, while Austria had the lowest at 37.6 per 100,000. This statistic depicts the incidence rate of colorectal cancer in the EU in 2022, by country and gender (per 100,000 population).

Introduction: Prevention of cancer has been identified as a major public health priority for Europe, and alcohol is a leading risk factor for various types of cancer. This contribution estimates the number of cancer cases that could have potentially been averted in 2018 in 4 European countries if an increase in alcohol excise taxation had been applied. Methods: Current country and beverage-specific excise taxation of 4 member states of the WHO European Region (Germany, Italy, Kazakhstan, and Sweden) was used as a baseline, and the potential impacts of increases of 20, 50, and 100% to current excise duties were modelled. A sensitivity analysis was performed, replacing the current tax rates in the 4 countries by those levied in Finland. The resulting increase in tax was assumed to be fully incorporated into the consumer price, and beverage-specific price elasticities of demand were obtained from meta-analyses, assuming less elasticity for heavy drinkers. Model estimates were applied to cancer incidence rates for the year 2018. Results: In the 4 countries, >35,000 cancer cases in 2018 were caused by alcohol consumption, with the highest rate of alcohol-attributable cancers recorded in Germany and the lowest in Sweden. An increase in excise duties on alcohol would have significantly reduced these numbers, with between 3 and 7% of all alcohol-attributable cancer cases being averted if taxation had been increased by 100%. If the 4 countries were to adopt an excise taxation level equivalent to the one currently imposed in Finland, an even higher proportion of alcohol-attributable cancers could be avoided, with Germany alone experiencing 1,600 fewer cancer cases in 1 year. Discussion/Conclusion: Increasing excise duties can markedly reduce cancer incidence in European countries.

BackgroundBreast cancer is the most common cancer in women worldwide. Considerable funding and efforts are invested in breast cancer research and healthcare, but only a fraction of this reaches women and healthcare systems in low income countries. Surgical treatment is an essential part of breast cancer care, but access to surgery is in general very limited in low income countries such as Uganda. In this study, the previously unknown nationwide rate of breast cancer surgery was investigated.Methods and findingsThis was a multicenter, retrospective study, investigating breast cancer surgery in the public healthcare system in Uganda. Data were collected from operating theater registries at primary, secondary and tertiary level healthcare centres throught the country, including 14 general hospitals, the 14 regional referral hospitals and the national referral hospital. Patients who underwent major surgery for breast cancer at these hospitals during 2013 and 2014 were included. The number of breast cancer procedures performed, geographical variation, level of healthcare staff performing surgery and patient characteristics were investigated. After correction for missing data, a total of 137 breast cancer procedures were performed each year within the public healthcare system, corresponding to 5.7% of the breast cancer incidence in the country at that time. Most procedures (n = 161, 59.0%) were performed at the national referral hospital by qualified surgeons. Many of the patients were young; 30.1% being less than 40 years old. The proportion of male breast cancers in the study was large (6.2%).ConclusionsThe rate of breast cancer surgery in Uganda is minimal and in several parts of the country breast cancer surgery is not performed at all. More resources must be directed towards breast cancer in low income countries such as Uganda. The fact that the patients were young calls for further research, prevention and treatment specifically targeting young women in the study setting.

ABSTRACT Background : The Covid-19 pandemic associated with the SARS-CoV-2 has caused very high death tolls in many countries, while it has had less prevalence in other countries of Africa and Asia. Climate and geographic conditions, as well as other epidemiologic and demographic conditions, were a matter of debate on whether or not they could have an effect on the prevalence of Covid-19. Objective : In the present work, we sought a possible relevance of the geographic location of a given country on its Covid-19 prevalence. On the other hand, we sought a possible relation between the history of epidemiologic and demographic conditions of the populations and the prevalence of Covid-19 across four continents (America, Europe, Africa, and Asia). We also searched for a possible impact of pre-pandemic alcohol consumption in each country on the two year death tolls across the four continents. Methods : We have sought the death toll caused by Covid-19 in 39 countries and obtained the registered deaths from specialized web pages. For every country in the study, we have analysed the correlation of the Covid-19 death numbers with its geographic latitude, and its associated climate conditions, such as the mean annual temperature, the average annual sunshine hours, and the average annual UV index. We also analyzed the correlation of the Covid-19 death numbers with epidemiologic conditions such as cancer score and Alzheimer score, and with demographic parameters such as birth rate, mortality rate, fertility rate, and the percentage of people aged 65 and above. In regard to consumption habits, we searched for a possible relation between alcohol intake levels per capita and the Covid-19 death numbers in each country. Correlation factors and determination factors, as well as analyses by simple linear regression and polynomial regression, were calculated or obtained by Microsoft Exell software (2016). Results : In the present study, higher numbers of deaths related to Covid-19 pandemic were registered in many countries in Europe and America compared to other countries in Africa and Asia. The analysis by polynomial regression generated an inverted bell-shaped curve and a significant correlation between the Covid-19 death numbers and the geographic latitude of each country in our study. Higher death numbers were registered in the higher geographic latitudes of both hemispheres, while lower scores of deaths were registered in countries located around the equator line. In a bell shaped curve, the latitude levels were negatively correlated to the average annual levels (last 10 years) of temperatures, sunshine hours, and UV index of each country, with the highest scores of each climate parameter being registered around the equator line, while lower levels of temperature, sunshine hours, and UV index were registered in higher latitude countries. In addition, the linear regression analysis showed that the Covid-19 death numbers registered in the 39 countries of our study were negatively correlated with the three climate factors of our study, with the temperature as the main negatively correlated factor with Covid-19 deaths. On the other hand, cancer and Alzheimer's disease scores, as well as advanced age and alcohol intake, were positively correlated to Covid-19 deaths, and inverted bell-shaped curves were obtained when expressing the above parameters against a country’s latitude. Instead, the (birth rate/mortality rate) ratio and fertility rate were negatively correlated to Covid-19 deaths, and their values gave bell-shaped curves when expressed against a country’s latitude. Conclusion : The results of the present study prove that the climate parameters and history of epidemiologic and demographic conditions as well as nutrition habits are very correlated with Covid-19 prevalence. The results of the present study prove that low levels of temperature, sunshine hours, and UV index, as well as negative epidemiologic and demographic conditions and high scores of alcohol intake may worsen Covid-19 prevalence in many countries of the northern hemisphere, and this phenomenon could explain their high Covid-19 death tolls. Keywords : Covid-19, Coronavirus, SARS-CoV-2, climate, temperature, sunshine hours, UV index, cancer, Alzheimer disease, alcohol.

According to cognitive market research, the global lung cancer therapeutics market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

The lungs are two spongy organs in the chest that control breathing. Lung cancer is the leading cause of cancer deaths worldwide. People who smoke have the greatest risk of lung cancer. The risk of lung cancer increases with the length of time and number of cigarettes smoked.
The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals
The chemotherapy segment dominated the lung cancer therapeutics market revenue in 2024 and is projected to be the fastest-growing segment during the forecast period. Chemotherapy goes throughout the entire body for tumor cells, whereas radiation and surgery target a single region of the body.
Moreover, this market dominance is a result of consumers' growing propensity to buy pharmaceuticals from hospital pharmacies due to the availability of a large variety of medicines.
There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Furthermore, the high maintenance cost of the instruments adds up to the total cost.

Market Dynamics of the Lung Cancer Therapeutics

Key Drivers of the Lung Cancer Therapeutics

The strong prevalence of lung cancer is notably driving market growth.

One of the most prevalent forms of cancer is lung cancer. Several reasons, including the aging population and lifestyle changes, have contributed to a notable increase in the number of new instances of cancer, particularly lung cancer, in recent years. In the United States, 6.2% of the population is at risk of developing lung cancer. Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals. • For instance, according to the 2022 report by the American Lung Association, while the disease remains the leading cause of cancer deaths among women and men, the survival rate over the past five years has increased from 21% nationally to 25% yet remains significantly lower among communities of color at 20%. Hence, the increasing prevalence of cancer and the need for effective treatment is likely to contribute to market growth. (Source:https://www.lung.org/research/state-of-lung-cancer/key-findings)

Rising pollution due to rapid industrialization increases the incidences of lung cancer

Air pollution (outdoor and indoor particulate matter and ozone) is closely linked to the rising prevalence of heart disease and strokes, lung cancer, lower respiratory infections, diabetes, and chronic obstructive pulmonary disease (COPD). The Global Burden of Disease Study Report (2019) ranks air pollution as the third leading cause of death worldwide. Globally, air pollution is responsible for 6.82 million deaths annually, of which 33% are caused by interior pollution and 66% by outdoor pollution. • For instance, According to the conference organized by the Associated Chambers of Commerce and Industry of India (ASSOCHAM), ‘Lung Cancer- Awareness, Prevention, Challenges & Treatment’, air pollution is the leading cause of the rise of lung cancer in the country. Around 63 out of the 100 most polluted places on earth belong to India. (Source:https://www.assocham.org/press-release-page.php?release-name=air-pollution-is-the-major-cause-of-lung-cancer-in-india-say-health-experts)

Restraints of the Lung Cancer Therapeutics

Regional disparities in treatment will hamper the market for lung cancer therapeutics

Lung cancer is the most prevalent cause of cancer-related deaths globally, and its impact is particularly felt in lower- and middle-income countries (LMICs), where access to early and effective diagnosis and treatment is often restricted. WHO data show that whereas 90% of cancer patients in high-income countries have access to therapy, only roughly 30% of cancer patients in low-income countries do. There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Furthermore, the high maintenance cost of the i...

According to cognitive market research, the global solid tumor therapeutics market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

A solid tumor is a mass of abnormal cells developing in several organs. Drugs and other therapeutic modalities target and treat solid tumors with reliable tumor treatments.
The cancer medications are administered by needle through an inserting tube into the body, even though chemotherapy has negative effects.
Pharmaceutical companies make investments in future research to release premium drugs. Large pharmaceutical companies are increasing the effectiveness of their R&D by working with R&D centers throughout the world and making significant expenditures in R&D to guarantee extended returns on investments.
The government's awareness campaigns to inform the public about early detection and treatment of breast cancer also contribute to the market's growth.
North America is anticipated to occupy a sizable portion of the market during the forecast period.

Market Dynamics of the Solid Tumor Therapeutics Market

Key Drivers of the Solid Tumor Therapeutics Market

The increasing prevalence of cancer is driving the global solid tumor therapeutics market growth.

The rising number of cases of various forms of metastatic cancer is expected to support market growth. Every day, the occurrence of many malignant illnesses rises. More tumor testing will be necessary for lung, colorectal, breast, and liver cancers, which will propel the market upward. Brain and neuroblastomas are the most prevalent forms of solid tumors; osteosarcoma and rhabdomyosarcoma are thought to be less common solid cancer types. The aging population and changing lifestyle habits, such as poor eating habits and inactivity, have contributed to a rise in the occurrence of cancer. • For instance, according to the European Breast Cancer Coalition 2022 report 1 in 11 women in the European Union develop breast cancer before the age of 74. (Source:https://www.europadonna.org/breast-cancer/ )

Rising government initiatives towards cancer cases significantly boost the market

The market for solid tumor cancer treatments is anticipated to expand between 2024 and 2031 as a result of growing government efforts, increased spending on research and development (R&D), advancements in sophisticated medical technology, and an increase in early cancer detection tests. Governments from many different nations have actively worked to raise knowledge about cancer treatment. Comprehensive cancer control programs are being implemented by several countries throughout the globe to lower cancer incidence and fatality rates. These initiatives frequently involve clinical trial assistance, medication development subsidies, and money for research and development. • For instance, the Indian government has started raising about treating cancer cases not only over offline media (boards, hoardings, in-store advertisements, in-mall activations) but also over online channels (social media channels, TV, radio, and others) (Source:https://assets.ey.com/content/dam/ey-sites/ey-com/en_in/topics/media-and-entertainment/2024/03/ey-in-india-s-media-entertainment-sector-is-innovating-for-the-future-03-2024-v2.pdf ) • For instance, in May 2022, the United States Department of Health and Human Services (HHS) awarded funding worth USD 5 million to community health centers to increase equitable access to life-saving cancer screenings. (Source:https://www.hhs.gov/about/news/2022/05/11/hhs-announces-5-million-funding-advance-equity-cancer-screening-health-centers.html )

Restraints of the Solid Tumor Therapeutics Market

Side effects associated with solid tumor therapeutics are hampering the global solid tumor therapeutics market growth.

Solid tumor therapy, like any other medication or medical procedure, can have several side effects. The quality of life of patients may be impacted by the toxicity and side effects of solid tumor therapies. An essential component of effective tumor therapy is controlling toxicity and side effects associated with the treatment. The patient and the therapy being employed might affect the individual side effects. The adverse effects of chemotherapy include an increased risk of infections, low blood...

In 2022, the mortality rate of pancreatic cancer in Europe was, among men, 17.2 per 100,000, while among women it stood at 6.3 per 100,000. For men, Romania had the highest mortality rate at 28.1 per 100,000, while Poland had the lowest at 9.4 per 100,000. For women, Romania also had the highest mortality rate at 11.5 per 100,000, while Malta had the lowest at 4 per 100,000. This statistic depicts the mortality rate of live cancer in Europe in 2022, by country and gender.